T Cell Lymphoma Clinical Trial
Official title:
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
This study will be a pilot study of sorafenib 400mg PO twice daily in refractory T-cell lymphomas including peripheral T-cell lymphoma (PTCL), angioimmunoblastic lymphadenopathy (AILD), cutaneous T cell lymphoma (CTCL), anaplastic large cell lymphoma (ALCL) and other transformed T-cell lymphomas with the primary objective of studying the biological effects of the multikinase inhibitor, sorafenib.
Primary objectives:
• To study the biological effects of sorafenib 400mg BID on the mitogen-activated protein
kinase (MAPK) pathway, specifically the inhibition of extracellular signal-regulated kinases
(ERK) phosphorylation, and to correlate with clinical activity in patients with T-cell
lymphoma.
Secondary objectives:
- To observe the clinical activity of sorafenib 400mg BID by determining response rate,
and progression free survival in patients with T-cell lymphoma. Duration of response and
duration of stable disease will also be measured.
- To determine the tolerability of sorafenib in patients with T-cell lymphoma.
Exploratory objectives:
- To observe the effects of sorafenib on T-cell subsets (CD4/CD8 ratio, and Tregs), and
the effects of sorafenib on the monocytoid population.
- To observe the effects of sorafenib on the serum cytokine profile.
- To observe the effects of sorafenib on the T-cell receptor pathway, i.e. Lck, ZAP-70,
and Syk.
- To observe changes in lymph node or skin morphology including tumor cell infiltrate,
vasculature, and the tumor microenvironment in patients treated with sorafenib by
performing serial biopsies of lymph nodes or skin.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04653649 -
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06420076 -
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04334174 -
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas
|
Phase 2 | |
| Recruiting |
NCT05367856 -
Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00798096 -
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT03770000 -
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05996185 -
Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT01430013 -
Trial of Endostar Combined With CHOPT for T Cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT04502446 -
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
|
Phase 1 | |
| Terminated |
NCT04973527 -
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
|
Phase 1 | |
| Recruiting |
NCT05230680 -
Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03672084 -
Allo-HSCT as First-line Consolidation in High-risk PTCL
|
||
| Recruiting |
NCT05852028 -
A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
|
||
| Enrolling by invitation |
NCT03628612 -
Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified
|
Phase 2 | |
| Recruiting |
NCT00974324 -
Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00877656 -
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05772728 -
Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)
|
N/A | |
| Completed |
NCT01300026 -
AMG 319 Lymphoid Malignancy FIH
|
Phase 1 | |
| Terminated |
NCT00880867 -
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04840875 -
Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma
|
Phase 1 |